Molecular studies by others, using doxorubicin-treated B cell lines and primary CLL cells, demonstrated that p53 directly transactivates miR15/miR16, resulting in decreased BCL2 mRNA/protein [58,59]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.